Taisho Pharmaceutical Co. and Tanabe Seiyaku Co. announced Monday that they will integrate operations under a holding company.
The decision is seen as a bid to survive cut-throat competition in the global market.
With combined sales worth 470 billion yen, the deal will create the nation's third-largest pharmaceutical company, following Takeda Chemical Industries Ltd., at 960 billion yen, and Sankyo Co., at 550 billion yen.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.